Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4259MR)

This product GTTS-WQ4259MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4259MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12689MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ5060MR IVTScrip™ mRNA-Anti-C5, CaCP-29(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CaCP-29
GTTS-WQ4549MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ779MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ12284MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ6671MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ9126MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
GTTS-WQ5534MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW